CSII provides better flexibility in basal insulin adjustments and management of EXE-associated hyper- or hypoglycemia than other insulin delivery methods in the management of early-onset and late-onset hypoglycemia after EXE [25,57,63]. The gene discussed is INS; the disease is Hypoglycemia.